Project Details
| Status | Active |
|---|---|
| Effective start/end date | 10/19/21 → 10/18/26 |
Funding
- Merck Sharp and Cohme Corporation: $17,750.00
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age
- Rupp, Richard (PI)
Project: Research project